$ACET

Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Other Events. Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis - Prula-cel shown to be generally well tolerated with no CRS greater than Grade 2 and no IEC-HS or ICANS -

Adicet Bio (ACET) will present clinical data for prula-cel, a potential lupus treatment, on September 28, 2026. The Phase 1 study results will be discussed in a webcast. Adicet focuses on developing allogeneic CAR-T therapies for autoimmune diseases and cancers.

Adicet Bio (ACET) released a September 2026 investor presentation, outlining clinical progress for prula-cel and ADI-212. Prula-cel is advancing toward a registrational pathway for LN/SLE, with pivotal data expected in the coming years. ADI-212 has received IND clearance for mCRPC, with clinical enrollment planned for 4Q 2026 and data expected in 1H/2H 2027. Initial clinical data for prula-cel showed clinical activity and favorable safety signals.

Adicet Bio completed the last patient visit for its Phase 1 prula-cel study in SLE, with topline data expected in September 2026. The FDA cleared the IND for ADI-212 in mCRPC, with Phase 1 enrollment starting in 4Q 2026. The company also announced progress on its in vivo CAR-T platform, with the first candidate expected to enter clinical trials in 2H 2027, according to the company.

Adicet Bio received FDA clearance to start a Phase 1 trial for ADI-212, an experimental cell therapy for advanced prostate cancer. The company plans to enroll patients in the final quarter of 2026. ADI-212 is an off-the-shelf therapy designed to target PSMA protein on prostate-cancer cells, with added modifications to enhance effectiveness against solid tumors.

Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Results of Operations and Financial Condition. Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates Company to provide a comprehensive Phase 1 clinical update for prulacabtagene leucel (prula-cel, formerly ADI-001), featuring data from 22 patients with lupus nephritis (LN) and systemic lupus

Adicet Bio, Inc. (ACET) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001720580 0001720580 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,

Ra Capital Management, L.P., a major shareholder in Adicet Bio (NASDAQ:ACET), recently increased its stake by purchasing 74,268 shares for $535,472.28 at an average cost of $7.21 per share. This transaction, occurring on February 19th, increased their total holdings to 1,107,873 shares, representing a 7.19% increase in their position. Other recent purchases by Ra Capital Management in February include 74,751 shares at $7.27 and 74,577 shares at $7.04.

Adicet Bio Inc (ACET) is projected to report a loss of $2.80 per share in its upcoming earnings. This earnings preview provides a brief financial outlook for the company based on Refinitiv data.

The average one-year price target for Adicet Bio (ACET) has significantly increased by 1,210.53% to $101.59 per share, up from the prior estimate of $7.75. This revised target is an average of analyst estimates ranging from $18.18 to $151.20, representing an 1,125.48% increase from its last closing price of $8.29. Institutional ownership in ACET remains high at 72 funds, holding 52,987K shares, and a bullish put/call ratio of 0.07.